Differential effect of human and murine polyclonal and monoclonal antisera on TNF-alpha production by human monocytes. 1993

G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
I Chair of Clinical Microbiology, Faculty of Medicine, La Sapienza University of Rome, Italy.

The capacity of human and murine polyclonal and monoclonal antibodies to inhibit lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-alpha) release from human monocytes was investigated. Human pooled immunoglobulin G (IVIG), human IgM monoclonal antibody (HA-1A) directed against the lipid A moiety of LPS, and murine IgG monoclonal antibody (MT-1F) raised in mice against antibiotic-treated Escherichia coli O6:K- were either added simultaneously with LPS to monocytes or preincubated for 1 h at 37 degrees C before being added to monocytes. TNF-alpha content in the monocyte supernatants was then tested. Simultaneous addition of increasing concentrations of IVIG (from 0.3 to 2.5 mg/ml) and 10 micrograms/ml of LPS to monocytes induced an enhanced release of TNF-alpha by monocytes in a dose dependent fashion. Preincubation of IVIG with LPS abolished the additive effect, but did not inhibit LPS-induced TNF-alpha release by monocytes. The simultaneous addition of LPS and HA-1A to monocytes had no additive effect nor did it inhibit TNF-alpha release. On the other hand, inhibition of TNF-alpha release was observed when HA-1A was preincubated with LPS before being added to monocytes. In all instances MT-1F inhibited TNF-alpha release when the monocytes were stimulated with smooth type LPS, but not with LPS isolated from rough mutants.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D016756 Immunoglobulins, Intravenous Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA. Antibodies, Intravenous,Human Intravenous Immunoglobulin,IV Immunoglobulin,IVIG,Intravenous Antibodies,Intravenous Immunoglobulin,Intravenous Immunoglobulins,Alphaglobin,Endobulin,Flebogamma DIF,Gamimmune,Gamimmune N,Gamimune,Gamimune N,Gammagard,Gammonativ,Gamunex,Globulin-N,IV Immunoglobulins,Immune Globulin Intravenous (Human),Immune Globulin, Intravenous,Immunoglobulins, Intravenous, Human,Intraglobin,Intraglobin F,Intravenous IG,Intravenous Immunoglobulins, Human,Iveegam,Modified Immune Globulin (Anti-Echovirus Antibody),Privigen,Sandoglobulin,Venimmune,Venoglobulin,Venoglobulin-I,Globulin N,Human Intravenous Immunoglobulins,Immunoglobulin, Human Intravenous,Immunoglobulin, IV,Immunoglobulin, Intravenous,Immunoglobulins, Human Intravenous,Immunoglobulins, IV,Intravenous Immune Globulin,Intravenous Immunoglobulin, Human,Venoglobulin I
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
April 1990, Pathologie-biologie,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
June 2002, Joint bone spine,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
January 1993, European cytokine network,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
September 1992, Immunology letters,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
January 1992, Mediators of inflammation,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
January 2003, Tuberculosis (Edinburgh, Scotland),
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
May 2001, Current protocols in immunology,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
May 2001, Current protocols in neuroscience,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
January 2008, Current protocols in cytometry,
G Raponi, and M T Lun, and A Gaeta, and M C Ghezzi, and C Nazzari, and C Mancini, and F Filadoro, and A Bartolazzi, and P Natali, and M Rozenberg-Arska
August 2008, Current protocols in immunology,
Copied contents to your clipboard!